WEBINAR SERIES

placeholder

CSSi LifeSciences and Innosphere Ventures, in collaboration with the Israel Economic Mission to the West Coast (USA), are presenting a free webinar series to early stage and emerging growth life science companies looking to make successful market entry and commercialization in the United States. The topics and descriptions of each webinar can be found below:

Alt Tag

Accelerating a Harmonized FDA Medical Device Strategy to Mitigate Risks, Time and Costs to Increase Commercial Success

JANICE CATTANO, MSN | CSSI LIFESCIENCES& CO.

October 19, 2020 10:30 AM ET / 7:30 AM PT

Part 1: Presentation by Janice Cattano, MSN | CSSi LifeSciences

The pathway from design to commercialization for a new medical device can be ambiguous and complex. Regulations and requirements change frequently and vary by notified bodies, country, level of risk, specific product claims, and intended use. Based on your medical device classification and current stage of development, there are a variety of US FDA CDRH submissions to consider. This program will help you to understand the regulatory pathways and strategies to address regulatory concerns and minimize additional FDA questions.

Part 2: Q&A with Michael Hassman I scPharmaceuticals

Following the presentation, there will be the opportunity to pose questions to Michael Hassman, Senior Vice President, Operations scPharmaceuticals. scPharmaceuticals is a pharmaceutical company focused on developing and commercializing innovative solutions to enhance the potential of outpatient care. The company is working with a device manufacturer with operations in Israel and Mr. Hassman can share key learnings.

Register

Designing a Strategic Harmonized FDA Roadmap for Success

Jim Sergi | CSSi LifeSciences

Time & Date To Be Determined

The pathway from discovery to commercialization for a new drug or medical device can be unclear and complex. Regulations and new guidance requirements from the US FDA can be ambiguous and are often subject to a reviewer's discretion. This program will help you gain an understanding of the applicable regulations, risks and requirements that will provide you with a roadmap to success.

Best Practices to Accelerate FDA Drug Development and Drive Value

Heidi Nelson-Keherly, PhD & Dan Rossignol, PhD | CSSi LifeSciences 

Time & Date To Be Determined

This program will help you to understand the importance of strategically aligning your preclinical and nonclinical research to support a US FDA drug approval. Vital issues will be considered, such as choosing the right indication and patient population within the competitive landscape, “must have” and “nice to have” studies, selection of appropriate test species, and outsourced facility selection criteria. In addition, we will discuss how to best leverage the FDA Special Designations (i.e., Orphan, Fast Track, Breakthrough, etc.) to accelerate your technology while mitigating risks and driving value.

Harmonizing the QMS Process

Ken Kleinhenz, MBA & Janice Cattano, MSN | CSSi LifeSciences

Time & Date To Be Determined

Quality Management Systems (QMS) are a worldwide requirement for marketing medical device products. Unlike the rest of world and Israel, the US FDA follows a unique QMS system, known as 21 CFR part 820. This program will help you to understand the differences, the US FDA CDRH requirements, and ways in which you can cost effectively harmonize your QMS to comply with both ISO 13485 and 21 CRF part 820 requirements.

US FDA Artificial Intelligence / Machine Learning Guidance

Ken Kleinhenz, MBA & Janice Cattano, MSN | CSSi LifeSciences

Time & Date To Be Determined

This webinar will discuss FDA guidance on the discussion paper entitled “Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)”. The FDA’s traditional medical device regulation was not designed for these new technologies and under the current approach to software modifications, the FDA anticipates that many of these AI/ML software changes to a device may need a premarket review. The total product lifecycle-based regulatory framework would allow modifications to be made from real-world learning and adaptation, while still ensuring that the safety and effectiveness of the software as a medical device is maintained.

SmartConnect™: Strategic Connections to Accelerate Your Business

Scott Silaika, MBA | CSSi LifeSciences

Time & Date To Be Determined

SmartConnect™ provides a strategic roadmap and direct access to a network of experts and capital to guide your journey from concept to market. Our extensive industry experience, deep subject matter expertise, market intelligence and network of strategic capital partners all work in harmony to rapidly accelerate your research discovery to a commercial reality. As you begin your journey, let CSSi LifeSciences start you off in the right direction.

How to Optimize and Leverage the US Capital Markets

Mike Freeman, CEO | Innosphere Ventures and Fund GP

Time & Date To Be Determined

Have you heard an investor express interest but not want to lead the deal? This webinar covers the strategy to get the first lead investor and syndicate other interested parties through proper investor relationship management.

Business Cultural Differences to Maximize your Collaborations in the US

Mike Freeman, CEO | Innosphere Ventures and Fund GP

Time & Date To Be Determined

Do you know how to develop relationships with your future customers in the US? This webinar discusses the optimal way to start, develop, and sell into your targeted accounts.

Understanding your Customers and Markets in the US

Ben Walker, Life Sciences Director | Innosphere Ventures

Time & Date To Be Determined

Do you understand your customers problems, processes, and current methods to manage those issues? Then your message can be heard and understood. This webinar outlines the customer discovery process that yields a methodology to maximize your value proposition to your target customers.

Understanding Market Sizing and Forecasting

Ben Walker, Life Sciences Director | Innosphere Ventures

Time & Date To Be Determined

Tops down forecasting from the Total addressable market is not enough. Investors want to know how you will obtain your first customers. This webinar discusses how to build a bottoms up forecast that is believable, actionable, and fundable.

FDA EUA COVID-19 Strategic Opportunities to Accelerate Technology Commercialization

HEIDI NELSON-KEHERLY, PHD & JANICE CATTANO, MSN | CSSI LIFESCIENCES 

Previous Webinar

Investors give you one chance to make a lasting impression. This webinar discusses the content required in the first and subsequent meetings to keep the relationship positive and beneficial to both parties.

VIEW RECORDING

US Investor Readiness -- Are You Ready?

Tim Jones | Innosphere Ventures  

Previous Webinar

Investors give you one chance to make a lasting impression. This webinar discusses the content required in the first and subsequent meetings to keep the relationship positive and beneficial to both parties.

VIEW RECORDING

Share Your Input

Let us know which topics you would like to see covered. 

Submit Your Vote
Cookies